1. Overcoming Clinical Inertia

3. Goals

4. Clinical Inertia

5. 2017 ACC/AHA/HFSA HF Guidelines

6. Natriuretic Peptide Screening for Prevention of HF 2017 ACC/AHA/HFSA Recommendations

7. NT-proBNP and Prognosis After ADHF Treatment

8. Specificity/Sensitivity of BNP Thresholds

9. The Importance of Serial NP Measurements for Prognostication in Chronic HF

10. Clinical Scenario

11. Same-Day Urgent HF Clinics

12. Cardiac Biomarkers in HF Many Settings

13. Thinking Out of the Box

14. Biomarker Indications for Use 2017 ACC/AHA/HFSA Recommendations

15. PARADIGM-HF: Reduction of NT-proBNP to ≤ 1000 pg/mL Leads to Better Outcomes

16. NT-proBNP As a Motivator for Patients

17. GUIDE-IT Study Design

18. GUIDE-IT Outcomes

19. Patient With Non-HF Signal for Risk

20. STOP-HF Study Design

21. STOP-HF Outcomes

22. PONTIAC Study Design

23. PONTIAC Outcomes

24. It Takes a Team!

25. Interprofessional Strategies to Overcoming Barriers

26. Barriers to Guideline Implementation

27. Strategies for Implementing Guideline-Directed Management

28. Summary

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)

32. Abbreviations (cont)